Kuehn Law Investigates Zynex Officers and Directors for Breach of Fiduciary Duty

Kuehn Law, PLLC, a law firm specializing in shareholder litigation, announced on July 21, 2026, an investigation into Zynex, Inc. (NASDAQ: ZYXI). The firm is examining whether certain officers and directors of the medical technology company may have breached their fiduciary duties to shareholders.

The investigation stems from a federal securities lawsuit that alleges Zynex misled investors regarding its business, operations, and prospects. The lawsuit claims the company failed to disclose critical information, including that it shipped products, such as electrodes, in excess of what was needed. As a result, Zynex allegedly inflated its revenue.

Furthermore, the claims state that Zynex's practice of submitting false claims drew scrutiny from insurers, including Tricare. This situation, the lawsuit posits, made it reasonably likely that Zynex would face adverse consequences, such as removal from insurance networks and penalties from the federal government. The suit contends that positive statements about the company were therefore materially misleading or lacked a reasonable basis.

Kuehn Law is seeking to hear from investors who currently own ZYXI stock and purchased it prior to March 13, 2023. The firm states it covers all case costs and does not charge its investor clients. Shareholders are advised to contact the firm promptly due to potential time limitations for asserting their rights.